<DOC>
	<DOCNO>NCT02185534</DOCNO>
	<brief_summary>This study open-label , randomise , three-way crossover study healthy male female subject , perform single centre . The objective study ass bioequivalence one test formulation ( Clopidogrel 75 mg tablet ( commercial blister KRKA ) two reference formulation ( Clopidogrel 75 mg tablet [ Plavix , source US Japan ] ) .</brief_summary>
	<brief_title>Clopidogrel Bioequivalence Study Healthy Subjects</brief_title>
	<detailed_description>Study evaluate bioequivalence orally administer European source clopidogrel tablet US Japanese source clopidogrel tablet .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Healthy male female subject age 18 55 year suitable vein cannulation repeat venepuncture . Females must negative pregnancy test screen admission clinical unit , must lactate non childbearing potential , confirm screen fulfil one follow criterion : Postmenopausal define amenorrhoea least 12 month follow cessation exogenous hormonal treatment folliclestimulating hormone ( FSH ) level postmenopausal range . Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . childbearing potential sexually active must use , partner , 2 approve method highly effective contraception time IMP administration 3 month last dose IMP . Have body mass index 18,5 29.9 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . Be able understand , read speak German language . Exclusion criterion History clinically significant disease disorder , opinion Investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . Current smoker smoke used nicotine product within previous 3 month . History haemophilia , von Willebrand 's disease , lupus anticoagulant , diseases/syndromes either alter increase propensity bleed . A personal history vascular abnormality include aneurysm ; personal history severe haemorrhage , haematemesis , melena , haemoptysis , severe epistaxis , severe thrombocytopenia , intracranial haemorrhage ; rectal bleeding within 1 year prior screening ; history suggestive peptic ulcer disease ; discretion Investigator . Use aspirin , ibuprofen , NSAIDS , drug know increase propensity bleed 2 week randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Clopidogrel , Zyllt , Plavix , Phase I , Healthy Subjects , Pharmacokinetics , Bioequivalence</keyword>
</DOC>